Sign up now!
Don't show this again
Sweepstakes Rules

We’re glad you’re enjoying Poultry Health Today.
Access is free but you’ll need to register to view more content.
Already registered? Sign In
Tap to download the app
REPORTSCollect articles and features into your own report to read later, print or share with others

Create a New Report


Read Later

Create a new report

Report title (required) Brief description (optional)
follow us

You must be logged in to edit your profile.

Sponsored by Zoetis

Sponsored By Zoetis


New FDA antibiotic guidelines: Why comply?

FDA’s new antimicrobial guidelines are strictly voluntary — to a degree. In the agency’s own words, they “do not establish legally enforceable responsibilities”; they merely “describe the FDA’s current thinking on a topic” and, unless otherwise indicated, should be viewed only as recommendations.

However, pharmaceutical companies that choose to comply with GFI 213 would effectively give up currently approved performance claims on antibiotics deemed medically important and place the remaining therapeutic uses under veterinary oversight — essentially making them prescription or Veterinary Feed Directive products instead of over the counter. Once that happens, veterinarians and animal producers cannot use these drugs for increased growth or feed efficiency.

So what incentives do drug sponsors have to comply?

Apparently plenty. Over the 3-year period following the release of the final version of GFI 213, FDA plans to evaluate the rate of adoption of its proposed changes. If it thinks the process needs a boost, it “will consider further action as warranted.”

In the meantime, the agency says it “recognizes the significance of the proposed changes” on the animal pharmaceutical industry, producers, the feed industry and veterinarians. It, therefore, opted for a voluntary phase-in to get everyone on board with its new direction.

‘Right way to go’

“We are very optimistic that the industry will work cooperatively with us,” William Flynn, deputy director for FDA’s Center of Veterinary Medicine, told Poultry Health Today in a recent interview. “We think this is the right way to go and it’s important to make progress. And that’s why we have set some fairly specific goals and timelines in connection with this.”

Even so, Flynn insisted it would not be a “completely open-ended” process. “We’re going to have to reassess where we are as we work through the voluntary process. We feel pretty confident, based on the interactions we’ve had with the industry, that this will be a successful approach and will have a high degree of cooperation. “But again, we’ll have to re-evaluate at the end of [3 years] and make a determination if we need to take any other steps.”

Measuring success

How will success be measured? There are many yardsticks available, but one clear indicator to Flynn will be the pace at which manufacturers drop performance claims — such as an increased rate of growth and feed efficiency — from the medically important antibiotics.

Under the new guidelines, performance claims and over-the-counter availability will be limited to antimicrobials not considered medically important.


Posted on July 2, 2014

tags: , ,
  • FDA: Some antibiotics still OK for production purposes

    New FDA guidelines that discourage using medically important antibiotics for promoting growth in food animals appear to have been well-received by both producers and most consumer activists. Change always brings misunderstandings and confusion, however — and the new...

  • How FDA will measure success of new VFD rule

    FDA has target dates in place for finalizing its data-collection plan and for determining whether efforts to promote the “judicious use” of antibiotics in food animals is having an impact on antibiotic resistance.

  • Sanderson Farms vet shares views on sustainability, antibiotic-free and FDA’s new antimicrobial guidelines

    Antibiotic-free poultry production is creating ethical conflicts for veterinarians while raising questions about sustainability, animal welfare and the industry’s ability to feed a growing population, says David French, DVM, of Sanderson Farms.

  • New FDA guidelines: Rating an animal antibiotic’s importance to humans

    The new industry guidelines issued by the US Food and Drug Administration in December suggest removing performance claims from food-animal antimicrobials deemed “medically important” to humans and reserving those feed additives for treating controlling and...

You must be logged in to edit your profile.

Google Translate is provided on this website as a reference tool. However, Poultry Health Today and its sponsor and affiliates do not guarantee in any way the accuracy of the translated content and are not responsible for any event resulting from the use of the translation provided by Google. By choosing a language other than English from the Google Translate menu, the user agrees to withhold all liability and/or damage that may occur to the user by depending on or using the translation by Google.